Enap-H tablets

Šalis: Armėnija

kalba: anglų

Šaltinis: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Parsisiųsti Pakuotės lapelis (PIL)
15-02-2017
Parsisiųsti Prekės savybės (SPC)
16-06-2021

Veiklioji medžiaga:

enalapril (enalapril maleate), hydrochlorothiazide

Prieinama:

KRKA d.d.

ATC kodas:

C09BA02

INN (Tarptautinis Pavadinimas):

enalapril (enalapril maleate), hydrochlorothiazide

Dozė:

10mg+ 25mg

Vaisto forma:

tablets

Vienetai pakuotėje:

(20/2x10/) in blister

Recepto tipas:

Prescription

Autorizacija statusas:

Registered

Leidimo data:

2017-02-10

Pakuotės lapelis

                                VOL:
I;P:
_110/475_
SPC,
Labelin
1.3.1
HHCTPYKUIIJI
no
Me.lUiUHHCKOMY
npHMeHeHHfO
neKapCTBeHHoro
Cpe}lCTBa
(O}lHOBpeMeHHo
nHCTOK-
BKJIa}lblW)
3Han®-H
TaGneTKH
10
Mr
_1_
25
Mr
ToprOBoe
HalBaHHe
3Han®-H
(Enap®-H)
Me*JlYR8pO}lROe
RenaTeRTOB8RRoe
H81BaRRe
Enalapril
/
Hydrochlorothiazide
I.
:1
f
f,
u'r
r. ~.
,s
v
~
I;
i ~
J
S
eOnaB
E ~
p ~
R T /
~ !, 1 A_
_~/r._
_01 /.{_
":~L!
r.
,.~
'~
I
T
I
__~ti'._
_0/,&_
JIeK8pnBeRRail
c1topMa
TaGneTrGf
Ka>l<}lrul
Ta6rreTKa
CO}lep:lKHT
10
Mr
3HaJIanpHna
MaJIeaTa
H
25
Mr
rH}lp0XJ10pTHa3H}la.
_Bcno.wozameJlbHble 6eUlecm6a:_
HaTplIJl
rH}lpOKap60HaT,
KpacHTenb
XHHonHHOBblH
)f(enT!.IH
(E 104),
naKT03bl
MOHOrH}lpaT,
KpaxMaJI
KYKYPY3HbIH,
KpaXMaJI
npe)f(eJ1aTHHH3HpoBaHHbIH,
TaJIbK,
MarHH.II
CTeapaT.
OnHC8RHe
KpyrrrbJe,
nJIOCKHe
Ta6rreTKH
)f(eJITOro
UBeTa,
co
CKOWeHHblMH
KpaJlMH
H HaCeqKOH
Ha
OJlHOH
CTopOHe.
Hace,{Ka
He npe}lHa3Ha'{eHa}lJ1J1
}lerreHHJI
Ta6neTKH
Ha '{aCTH.
cJ)apMalConpaneBTR'IeCKaR
rpynna
I1HrH6HTopbl
ATI
B KOM6HHaUHH
C JlHYpeTHKaMH.
KO}l
A
TX:
C09BA02.
cJ)apMaICOJlOI'R"IeCICHe cBoiicTBa
_(f>apMaKoouHOMuKa_
KOM6J.1HJ.lpOBaHRbIH
npenapaT,
}leHcTBHe
KOToporo
o6YCJI0BJ1eHO
CBoHcTBaMH
KOMnOHeRTOB,
BXO)1J1IUHX B ero
COCTaB.
_3HaJlanpUlla Maneam_
3HananpHJI
JlBJUleTCJI
HHrH6HTopOM
An.
B
opraRH3Me
OR
6b1cTPO
MeTa6onH3HpYeTCJI
B
:3HaJlanpHJlaT,
KOTOPbrH
lIBJ1J1eTClI
CHnbHblM
HHrn6HTopoM
ATIll>.
OCHOBHble
3cpcpeKTbl
IofHrll6HpOBaHHJI
An:
CHH)f(eHHe
KOHueRTPaUHH
aHrHOTeH3HHa
II
H
aJIb)1oCTepORa
B
UHpl
                                
                                Perskaitykite visą dokumentą
                                
                            

Prekės savybės

                                PI_Text005187_1
– Updated:
Page 1 of 18
1.
NAME OF THE MEDICINAL PRODUCT
Enap
®
-H 10 mg/25 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Enap-H 10 mg/25 mg tablet contains 10 mg enalapril maleate, which
is equivalent to 7.64 mg
enalapril, and 25 mg hydrochlorothiazide.
Excipients:
lactose
114.02 mg
quinolone
yellow (E104)
0.06 mg
sodium
5.1 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
Enap-H 10 mg/25 mg tablets: yellow, round, flat, scored on one side
with beveled edges.
The score
line is not intended for breaking the tablet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Arterial hypertension (patients for whom the combination therapy is
prescribed).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The drug is intended for oral treatment.
The dosage of the drug is based primarily on the experience with its
active substance enalapril
maleate.
The usual dose is one tablet once daily. If required, the dose may be
increase to two tablets once daily.
For most patients, 20 mg (exceptionally 40 mg) enalapril maleate or 50
mg hydrochlorothiazide a day
is sufficient; therefore, not more than two Enap-H 10 mg/25 mg tablets
a day are recommended. If no
satisfactory response is achieved, addition of a second drug or
changed therapy is recommended (see
sections 4.3, 4.4, 4.5 and 5.1).
_Prior diuretic therapy_
Symptomatic hypotension may occur following the initial dose of the
drug; this is more likely in
patients who are volume and/or salt depleted as a result of prior
diuretic therapy. The diuretic therapy
should be discontinued for 2-3 days prior to initiation of therapy
with Enap-H 10 mg/25 mg.
_Dosage in renal insufficiency_
Thiazide diuretics may not be appropriate for patients with renal
impairment. They are ineffective in
patients with creatinine clearance values of 0.5 ml/s or less (i.e.
moderate and severe renal
insufficiency).
CONFIDENTIAL
Enap-H 10 mg/25 mg tablet, Enap-HL 10 mg/12.5 mg
tablet
VOL: 1; P: 44 / 792
PI_Text005187_1
– Updated:
Page 2 of 18
In pat
                                
                                Perskaitykite visą dokumentą
                                
                            

Dokumentai kitomis kalbomis

Pakuotės lapelis Pakuotės lapelis rusų 16-06-2021

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją